Protein co-expression networks identified from HOT lesions of ER+HER2-Ki-67high luminal breast carcinomas.
Adult
Aged
Antineoplastic Agents
/ therapeutic use
Breast Neoplasms
/ drug therapy
Female
Gene Expression Regulation, Neoplastic
/ genetics
Heat-Shock Response
/ genetics
Humans
Ki-67 Antigen
/ metabolism
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Protein Interaction Maps
/ genetics
Proteome
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 01 2021
18 01 2021
Historique:
received:
30
10
2020
accepted:
05
01
2021
entrez:
19
1
2021
pubmed:
20
1
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative/Ki-67-high (ER+HER2-Ki-67high) luminal breast cancer have a worse prognosis and do not respond to hormonal treatment and chemotherapy. This study sought to identify disease-related protein networks significantly associated with this subtype, by assessing in-depth proteomes of 10 lesions of high and low Ki-67 values (HOT, five; COLD, five) microdissected from the five tumors. Weighted correlation network analysis screened by over-representative analysis identified the five modules significantly associated with the HOT lesions. Pathway enrichment analysis, together with causal network analysis, revealed pathways of ribosome-associated quality controls, heat shock response by oxidative stress and hypoxia, angiogenesis, and oxidative phosphorylation. A semi-quantitative correlation of key-protein expressions, protein co-regulation analysis, and multivariate correlation analysis suggested co-regulations via network-network interaction among the four HOT-characteristic modules. Predicted highly activated master and upstream regulators were most characteristic to ER-positive breast cancer and associated with oncogenic transformation, as well as resistance to chemotherapy and endocrine therapy. Interestingly, inhibited intervention causal networks of numerous chemical inhibitors were predicted within the top 10 lists for the WM2 and WM5 modules, suggesting involvement of potential therapeutic targets in those data-driven networks. Our findings may help develop therapeutic strategies to benefit patients.
Identifiants
pubmed: 33462336
doi: 10.1038/s41598-021-81509-9
pii: 10.1038/s41598-021-81509-9
pmc: PMC7814020
doi:
Substances chimiques
Antineoplastic Agents
0
Ki-67 Antigen
0
Proteome
0
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1705Références
J Cell Physiol. 2015 Jan;230(1):191-8
pubmed: 24931902
Sci Rep. 2020 Aug 12;10(1):13604
pubmed: 32788598
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
Cancer Res. 2015 Jun 15;75(12):2445-56
pubmed: 26077471
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Mol Cell. 2017 Feb 16;65(4):751-760.e4
pubmed: 28132843
Front Genet. 2015 Apr 10;6:141
pubmed: 25914721
Sci Rep. 2020 Jul 2;10(1):10881
pubmed: 32616892
Anticancer Agents Med Chem. 2020;20(7):758-767
pubmed: 32013835
BMC Cancer. 2014 Jan 20;14:32
pubmed: 24444383
Sci Rep. 2019 May 17;9(1):7507
pubmed: 31101846
Nat Methods. 2007 Mar;4(3):207-14
pubmed: 17327847
Annu Rev Pharmacol Toxicol. 2007;47:89-116
pubmed: 16968214
Nat Biotechnol. 2019 Nov;37(11):1361-1371
pubmed: 31690884
Breast Cancer Res Treat. 2019 Nov;178(2):451-458
pubmed: 31422497
BMC Syst Biol. 2014;8 Suppl 4:S11
pubmed: 25521941
Chem Biol. 2014 Apr 24;21(4):441-452
pubmed: 24613018
Oncogene. 2015 Apr 9;34(15):1890-8
pubmed: 24882575
Breast Cancer Res. 2016 Jun 01;18(1):58
pubmed: 27246191
PLoS One. 2019 Jun 5;14(6):e0217105
pubmed: 31166966
Cell Mol Biol (Noisy-le-grand). 2015 May 28;61(2):94-7
pubmed: 26025410
Int J Med Sci. 2018 Aug 10;15(12):1320-1328
pubmed: 30275758
Mol Cancer Ther. 2010 Aug;9(8):2365-76
pubmed: 20682644
BMC Cancer. 2016 Sep 15;16(1):734
pubmed: 27634735
Breast Cancer Res. 2012 Dec 05;14(6):R153
pubmed: 23216744
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Cancer Biol Ther. 2010 Aug 1;10(3):223-31
pubmed: 20523116
Sci Rep. 2016 Apr 20;6:24606
pubmed: 27094683
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
Mol Cell Proteomics. 2005 Oct;4(10):1487-502
pubmed: 15979981
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340135
Sci Rep. 2018 Sep 17;8(1):13904
pubmed: 30224719
Expert Rev Proteomics. 2019 Sep;16(9):761-772
pubmed: 31402712
Front Oncol. 2020 Aug 25;10:1494
pubmed: 32983988
Oncogene. 2018 Apr;37(14):1869-1884
pubmed: 29353882
J Clin Invest. 2015 Apr;125(4):1648-64
pubmed: 25774502
Histopathology. 2009 Sep;55(3):313-20
pubmed: 19723146
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 19;373(1738):
pubmed: 29203706
Breast Cancer Res. 2010;12(3):R44
pubmed: 20584310
Proteomics Clin Appl. 2018 Nov;12(6):e1800015
pubmed: 29888431
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
BMC Cancer. 2016 Oct 22;16(1):821
pubmed: 27770790
Oncotarget. 2015 Sep 8;6(26):22890-904
pubmed: 26274893
Angiogenesis. 2019 Feb;22(1):117-131
pubmed: 30132150
Oncol Rep. 2011 Mar;25(3):637-44
pubmed: 21206984
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Cancer Gene Ther. 2017 Aug;24(8):333-341
pubmed: 28799567
Oncotarget. 2019 Oct 15;10(57):6021-6037
pubmed: 31666932
Elife. 2014 Sep 16;3:e03164
pubmed: 25233275
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
J Proteomics. 2010 Apr 18;73(6):1089-99
pubmed: 19948256
Biotechniques. 2005 Jun;Suppl:32-5
pubmed: 16528915
Oncotarget. 2016 Sep 13;7(37):59640-59651
pubmed: 27458152
Anal Chem. 2005 Oct 1;77(19):6218-24
pubmed: 16194081